Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

100.09USD
31 Jul 2014
Price Change (% chg)

$-2.21 (-2.16%)
Prev Close
$102.30
Open
$101.61
Day's High
$101.83
Day's Low
$100.05
Volume
2,784,202
Avg. Vol
1,821,532
52-wk High
$106.74
52-wk Low
$85.50

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.57
Market Cap (Mil.): $288,752.00
Shares Outstanding (Mil.): 2,822.60
Dividend: 0.70
Yield (%): 2.74

Financials

  JNJ.N Industry Sector
P/E (TTM): 18.91 35.82 36.29
EPS (TTM): 5.41 -- --
ROI: -- 18.85 18.13
ROE: -- 19.57 18.95
Search Stocks

J&J seeks return of device seen as possibly raising cancer risk

- Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

31 Jul 2014

J&J seeks return of device seen as possibly raising cancer risk

July 30 - Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

31 Jul 2014

Europe backs new leukaemia drugs from J&J and Gilead

LONDON, July 25 - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

25 Jul 2014

US STOCKS-Wall St dips after Yellen comments on valuations

* New York manufacturing hits highest level since April 2010

15 Jul 2014

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

July 15 - Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

15 Jul 2014

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

24 Jun 2014

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON, June 23 - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

24 Jun 2014

Medtronic to buy Covidien for $42.9 billion, rebase in Ireland

REUTERS - U.S. medical device maker Medtronic Inc said on Sunday it had agreed to buy Covidien Plc for $42.9 billion in cash and stock and move its executive base to Ireland in the latest transaction aiming for lower corporate tax rates abroad.

16 Jun 2014

J&J links up with GSK-led group on new two-drug HIV tablet

LONDON, June 12 - Johnson & Johnson has linked up with ViiV Healthcare - a specialist HIV company majority-owned by GlaxoSmithKline - to develop a new AIDS medicine combining two drugs in a single tablet.

12 Jun 2014

Earnings vs. Estimates

Search Stocks